7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease

Hereditary Coagulation Factor Deficiencies & von Willebrand Disease

Secondary hemostasis is the enzymatic cascade that culminates in the explosive generation of thrombin (Factor IIa) and the deposition of an insoluble, crosslinked fibrin polymer meshwork that stabilizes the primary platelet plug. Deficiencies or functional defects in coagulation factors result in characteristic bleeding phenotypes ranging from localized mucocutaneous hemorrhage to catastrophic, spontaneous deep-tissue hemarthroses and intracranial bleeding.

                             [ COAGULATION CASCADE ARCHITECTURE ]

     INTRINSIC PATHWAY (Contact Activation)             EXTRINSIC PATHWAY (Tissue Injury)
     ─────────────────────────────────────             ──────────────────────────────────
     FXII, Prekallikrein, HMWK ──► FXIIa               Subendothelial Tissue Factor (TF)
                  │                                                   │
                  ▼                                                   ▼
                FXIa                                            TF : FVIIa Complex
                  │                                                   │
                  ▼                                                   │
       FIX ──────────────► FIXa + FVIIIa                              │
                             (Intrinsic Tenase)                       │
                                     │                                │
                                     └──────────────┬─────────────────┘
                                                    ▼
                                        COMMON PATHWAY
                                        ──────────────
                                              FXa
                                               │  + FVa, Ca2+, Phospholipids
                                               ▼  (Prothrombinase Complex)
                                      Prothrombin (FII) ──► Thrombin (FIIa)
                                                                │
                                     ┌──────────────────────────┴──────────────────────────┐
                                     ▼                                                     ▼
                          Fibrinogen (FI) ──► Soluble Fibrin                  FXIII ──► FXIIIa (Transglutaminase)
                                                    │                                      │
                                                    └──────────────────┬───────────────────┘
                                                                       ▼
                                                           Insoluble Crosslinked Fibrin Clot

---

Hereditary Hemophilias: Hemophilia A, B, and C

Inherited single-factor deficiencies in the intrinsic tenase complex (Factor VIII and Factor IX) account for the overwhelming majority of severe inherited bleeding disorders.

                                  [ INTRINSIC TENASE COMPLEX ]

                          Activated Platelet Phospholipid Surface (PS)
                                               │
                  ┌────────────────────────────┴────────────────────────────┐
                  ▼                                                         ▼
     Factor IXa (Serine Protease)                              Factor VIIIa (Cofactor)
     [ Deficient in Hemophilia B ]                             [ Deficient in Hemophilia A ]
                  │                                                         │
                  └────────────────────────────┬────────────────────────────┘
                                               │ + Ca2+
                                               ▼
                                  Factor X ────────► Factor Xa

1. Hemophilia A (Classic Hemophilia)

• Etiology and Genetics: Hemophilia A is an X-linked recessive coagulopathy caused by mutations in the F8 gene located on the long arm of the X chromosome ($Xq28$). Approximately 45% of severe cases result from a major structural rearrangement known as the intron 22 inversion, while single base substitutions, insertions, and deletions account for the remainder. Spontaneous de novo mutations occur in roughly 30% of new cases without prior family history.
• Pathophysiology: Factor VIII serves as the non-enzymatic protein cofactor that accelerates the activation of Factor X by Factor IXa by greater than 200,000-fold on activated phospholipid membranes. In the absence of FVIII, the propagation phase of thrombin generation is severely impaired, yielding frail clots susceptible to premature fibrinolysis.
• Clinical Stratification by Plasma Activity:
  • Severe (<1% / <0.01 IU/mL FVIII Activity): Manifests in infancy with frequent, spontaneous hemarthroses (joint bleeding predominantly targeting knees, elbows, and ankles), deep intramuscular hematomas, pseudotumors, retroperitoneal hemorrhage, and excessive bleeding during circumcision or eruption of deciduous teeth. Chronic recurrent hemarthroses induce proliferative synovitis and crippling hemophilic arthropathy.
  • Moderate (1–5% / 0.01–0.05 IU/mL FVIII Activity): Spontaneous bleeding is uncommon; severe hemorrhage occurs secondary to minor trauma, intramuscular injections, or minor surgical interventions.
  • Mild (5–40% / 0.05–0.40 IU/mL FVIII Activity): Asymptomatic during daily life; diagnosed late in adolescence or adulthood after unexpected profuse hemorrhage following major dental extractions, trauma, or surgical procedures.
• Laboratory Profile:
  • aPTT: Markedly prolonged (intrinsic pathway defect).
  • PT / INR: Strictly normal (extrinsic pathway intact).
  • Bleeding Time / PFA-100: Strictly normal (platelet plug formation intact).
  • Platelet Count: Strictly normal.
  • vWF Antigen & Activity: Strictly normal.
  • Confirmatory Test: One-stage clot-based Factor VIII activity assay demonstrating decreased FVIII clotting activity.
• Therapeutic Management:
  • Factor VIII Replacement: Recombinant FVIII (rFVIII) or plasma-derived FVIII concentrates.
  • Emicizumab (Hemlibra): A recombinant, humanized, bispecific monoclonal antibody engineered with dual antigen-binding arms that bridge activated Factor IX (FIXa) and Factor X (FX). By mimicking the spatial scaffolding function of activated FVIIIa, emicizumab restores tenase enzymatic activity and thrombin generation regardless of the presence of anti-FVIII neutralizing alloantibody inhibitors.
  • Desmopressin (DDAVP): Stimulates release of endogenous subendothelial FVIII/vWF stores in patients with mild Hemophilia A.

2. Hemophilia B (Christmas Disease)

• Etiology and Genetics: X-linked recessive disorder caused by mutations in the F9 gene located on $Xq27$. Named after Stephen Christmas, the first patient identified with this distinct molecular entity in 1952.
• Pathophysiology: Deficiency of Factor IX, a vitamin K-dependent serine protease that complexes with FVIIIa on platelet membranes to form the intrinsic tenase complex.
• Clinical Presentation: Clinically indistinguishable from Hemophilia A. Stratified into identical severity categories: Severe ($<1%$), Moderate ($1\text{--}5%$), and Mild ($5\text{--}40%$).
• Laboratory Profile: Prolonged aPTT, strictly normal PT, normal TT, normal fibrinogen, and normal platelet parameters. Confirmed via specific one-stage Factor IX activity assay showing decreased FIX levels.
• Therapeutic Management: Recombinant FIX (rFIX) concentrates, plasma-derived FIX, or extended half-life Fc-fusion/PEGylated FIX formulations.

3. Hemophilia C (Rosenthal Syndrome / Factor XI Deficiency)

• Etiology and Genetics: Autosomal recessive coagulopathy caused by mutations in the F11 gene on chromosome 4 ($4q35$). Highly prevalent among individuals of Ashkenazi Jewish descent (heterozygote carrier frequency approaches 8–10%).
• Pathophysiology & Clinical Bleeding Phenotype: Factor XI is activated by Factor XIIa and undergoes self-activation via thrombin feedback to sustain intrinsic cascade amplification. Unlike Hemophilias A and B, spontaneous hemarthroses and muscle hematomas are exceptionally rare in Hemophilia C. Bleeding is typically mild and unpredictable, manifesting postoperatively following interventions involving tissues with high endogenous fibrinolytic activity (e.g., tonsillectomy, dental extractions, prostatectomy, and gynecologic surgery).
• Clinical-Laboratory Discordance: Plasma FXI coagulant activity levels correlate poorly with clinical hemorrhagic tendency. Severely deficient homozygous individuals ($<1\text{--}15%$ FXI) may experience minimal bleeding, whereas partial heterozygotes ($30\text{--}50%$ FXI) may bleed excessively post-trauma.
• Laboratory Profile: Prolonged aPTT with normal PT/INR, corrected by 1:1 mixing study, confirmed with specific Factor XI activity assay.

---

Other Inherited Factor Deficiencies

                    [ LABORATORY SCREENING MATRIX FOR RARE DEFICIENCIES ]

            PT Prolonged / aPTT Normal  ──────►  Factor VII Deficiency
            PT Normal / aPTT Prolonged  ──────►  FXII, Prekallikrein, HMWK (No Bleeding!)
            PT Normal / aPTT Normal     ──────►  Factor XIII Deficiency (Delayed Bleeding)
            PT Prolonged / aPTT Prolonged ────►  Common Pathway Deficiencies (FX, FV, FII, FI)

Factor XIII Deficiency (Fibrin Stabilizing Factor)

• Molecular Genetics & Structure: Autosomal recessive transglutaminase deficiency. Plasma FXIII circulates as a heterotetramer ($A_2B_2$ subunits); cellular FXIII in platelets and monocytes exists as an $A_2$ homodimer. Activated by thrombin ($Ca^{2+}$-dependent) to form Factor XIIIa.
• Biological Function: Factor XIIIa catalyzes the covalent formation of isopeptide crosslinks between $\epsilon$-lysyl and $\gamma$-glutamyl residues of adjacent fibrin monomers (forming covalent $\gamma$-dimers and $\alpha$-polymers). This crosslinking transforms fragile, soluble hydrogen-bonded fibrin polymers into a structurally stable, elastic, and plasmin-resistant insoluble hemostatic mesh.
• Clinical Presentation: Normal primary hemostasis and initial clot formation occur normally; however, the clot rapidly destabilizes within hours:
  • Delayed umbilical cord bleeding in neonates (occurs 2 to 7 days after cord separation in $>80%$ of cases).
  • High incidence of spontaneous, life-threatening intracranial hemorrhage (ICH) ($>30%$ of untreated individuals).
  • Recurrent, spontaneous first-trimester pregnancy loss and miscarriages.
  • Poor wound healing, abnormal scar tissue development, and keloid formation.
• Laboratory Hallmarks:
  • PT, aPTT, Thrombin Time (TT), Fibrinogen, and Platelet Count are ALL STRICTLY NORMAL. Routine screening tests end at the formation of an initial fibrin gel, which does not require FXIIIa covalent crosslinking.
  • Diagnostic Screening Assay: 5M Urea / 1% Monochloroacetic Acid Clot Solubility Test.
    • Principle: Citrated patient plasma is clotted with calcium chloride or thrombin and placed in a 5 Molar urea (or 1% monochloroacetic acid) solution at $37^\circ\text{C}$.
    • Normal Interpretation: Normal clots crosslinked by FXIIIa remain completely intact, insoluble, and stable for $>24$ hours.
    • FXIII Deficiency: In severe FXIII deficiency ($<1\text{--}5%$ activity), the uncrosslinked fibrin mesh dissolves rapidly, showing complete clot dissolution in <1 to 2 hours.
  • Confirmatory Assays: Quantitative chromogenic transglutaminase activity assays and photometric ammonia-release kinetic assays.

Factor VII Deficiency

• Characteristics: Autosomal recessive disorder; the only single-factor deficiency that produces an isolated prolonged PT with a strictly normal aPTT.
• Clinical Severity: Correlates with FVII levels; severe deficiency ($<1%$) presents with early CNS bleeding, hemarthroses, and severe epistaxis.

Contact Activation Factor Deficiencies (FXII, Prekallikrein, HMWK)

• The Paradigm: Deficiencies in Factor XII (Hageman Factor), Prekallikrein (Fletcher Factor), or High-Molecular-Weight Kininogen (HMWK / Fitzgerald Factor).
• Laboratory Finding: Markedly prolonged aPTT (often $>100$ seconds).
• Clinical Presentation: NO in vivo clinical bleeding tendency whatsoever. Patients undergo major surgeries without abnormal blood loss because in vivo coagulation is initiated physiologically via the Tissue Factor : FVIIa pathway rather than contact activation.
• Paradoxical Thrombotic Risk: Deficiencies in FXII, Prekallikrein, and HMWK impair the contact-dependent activation of the fibrinolytic system (plasminogen activation) and bradykinin generation, conferring an increased risk of venous thromboembolism (VTE) and myocardial infarction.

---

von Willebrand Disease (vWD)

von Willebrand Disease (vWD) is the most common inherited bleeding disorder, affecting approximately 1% of the global population. It arises from quantitative or qualitative defects in von Willebrand Factor (vWF), an adhesive multimeric glycoprotein encoded by the VWF gene on chromosome 12 ($12p13.3$).

                                [ vWF SYNTHESIS & DUAL FUNCTION ]

     Endothelial Weibel-Palade Bodies           Megakaryocyte Alpha-Granules
                    │                                         │
                    └────────────────────┬────────────────────┘
                                         ▼
                         Ultra-Large vWF Multimers (UL-vWF)
                                         │
                                         ▼ Cleaved by ADAMTS13
                         Plasma High-Molecular-Weight Multimers
                                         │
                 ┌───────────────────────┴───────────────────────┐
                 ▼                                               ▼
       [ PRIMARY HEMOSTASIS ]                         [ SECONDARY HEMOSTASIS ]
   - A3 domain binds Subendothelial Collagen      - D'/D3 domain non-covalently binds
   - A1 domain binds Platelet GPIbα (CD42b)         and stabilizes Factor VIII in plasma
   - Mediates High-Shear Platelet Adhesion        - Extends FVIII Half-Life (2h ──► 12h)

vWD Classification & Diagnostic Subtypes

Specialized Laboratory Diagnostic Panel for vWD

1. vWF Antigen (vWF:Ag): Quantifies total circulating vWF protein mass via automated Latex Immunoassays (LIA) or ELISA.
2. Ristocetin Cofactor Activity (vWF:RCo): Evaluates functional capacity of patient plasma vWF to bind platelet GPIb in the presence of standard ristocetin ($1.0\text{--}1.25\text{ mg/mL}$) using lyophilized, formalin-fixed normal platelets.
3. vWF:RCo to vWF:Ag Ratio: A ratio $<0.7$ indicates a qualitative functional defect (Type 2A, 2B, or 2M), whereas a ratio $\ge 0.7$ indicates a concordant quantitative reduction (Type 1).
4. Factor VIII Coagulant Activity (FVIII:C): Standard one-stage aPTT-based factor assay. Severely decreased in Type 2N and Type 3.
5. Ristocetin-Induced Platelet Agglutination (RIPA): Patient Platelet-Rich Plasma (PRP) is challenged with low-dose ristocetin ($0.5\text{ mg/mL}$):
   • Normal / Type 1 / Type 2A / Type 2M / Type 3: No agglutination at low dose ($0.5\text{ mg/mL}$).
   • Type 2B vWD: Induces robust hyper-agglutination at $0.5\text{ mg/mL}$ because the mutant vWF binds GPIb spontaneously. (Platelet-type pseudo-vWD produces an identical low-dose RIPA curve due to an intrinsic mutation in platelet GP1BA).
6. Agarose Gel Electrophoresis (vWF Multimer Analysis): Resolves low-, intermediate-, and high-molecular-weight multimer fractions using SDS-agarose gel electrophoresis with radiolabeled or enzyme-conjugated anti-vWF antibodies.

                                  [ vWD MULTIMER GEL PROFILES ]

  Top (High MW)    ═══════════════                   ═══════════════
                   ═══════════════                   ═══════════════
  Middle (Med MW)  ═══════════════                   ═══════════════
                   ═══════════════  ═══════════════  ═══════════════
  Bottom (Low MW)  ═══════════════  ═══════════════  ═══════════════
                    [ NORMAL ]        [ TYPE 2A/2B ]   [ TYPE 1 & 2M ]    [ TYPE 3 ]
                    Full Ladder       Loss of HMWM       Full Ladder      Empty Gel

Therapeutic Principles in vWD

• Desmopressin (DDAVP / 1-deamino-8-D-arginine vasopressin): Induces exocytosis of Weibel-Palade bodies via $V_2$ vasopressin receptor stimulation, increasing plasma vWF and FVIII 3- to 5-fold within 30–60 minutes. First-line therapy for Type 1 vWD.
• Contraindication in Type 2B: DDAVP is strictly contraindicated in Type 2B vWD because releasing mutant vWF with hyper-affinity for GPIb triggers immediate widespread intravascular platelet agglutination, precipitating acute consumptive thrombocytopenia and microvascular thrombosis.
• vWF / FVIII Concentrates (Humate-P, Wilate): Plasma-derived, viral-inactivated concentrates containing intact high-molecular-weight vWF multimers and FVIII; indicated in Type 2A, Type 2B, Type 2M, Type 2N, Type 3, and severe Type 1 refractory to DDAVP.
• Recombinant vWF (Vonvendi): Highly purified r-vWF containing ultra-large multimers free of human albumin or FVIII.

---